scholarly journals BCL11A is a triple-negative breast cancer gene with critical functions in stem and progenitor cells

2015 ◽  
Vol 6 (1) ◽  
Author(s):  
Walid T. Khaled ◽  
Song Choon Lee ◽  
John Stingl ◽  
Xiongfeng Chen ◽  
H. Raza Ali ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Progenitor Cells ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Cancer Gene ◽  
Stem And Progenitor Cells ◽  
Breast Cancer Gene

scholarly journals STAT3 and GR cooperate to drive basal-like triple negative breast cancer gene expression and proliferation

2019 ◽  
Author(s):  
Megan E. Conway ◽  
Joy M. McDaniel ◽  
James M. Graham ◽  
Katrin P. Guillen ◽  
Patsy G. Oliver ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Gene Expression ◽  
Transcription Factors ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Gene Expression Program ◽  
Luminal Breast Cancer ◽  
Cancer Gene ◽  
Expression Program ◽  
Breast Cancer Gene

AbstractBreast cancers can be divided into subtypes with different prognoses and treatment responses based on global gene expression differences. Luminal breast cancer gene expression and proliferation are driven by the transcription factors Estrogen Receptor α (ER), FOXA1 and GATA3. Targeting ER is the most effective therapy for treating luminal breast cancer because ER is the master regulator of the luminal gene expression program. In contrast, it is unclear which transcription factors are responsible for driving the gene expression signature that defines basal-like triple negative breast cancer, and there are no targeted therapies approved to treat this aggressive subtype of the disease. This study utilized integrated analysis of DNA methylation, chromatin accessibility, transcription factor binding, and gene expression in large collections of breast cancer cell lines and patient tumors to identify transcription factors responsible for the basal-like gene expression program. The results of this study indicate that glucocorticoid receptor (GR) and signal transducer and activator of transcription 3 (STAT3) bind to the same genomic regulatory regions that are specifically open and unmethylated in basal-like breast cancer. These transcription factors cooperate to regulate expression of hundreds of genes in the basal-like gene expression signature and these downstream genes are associated with poor prognosis in patients. Furthermore, combination treatment with small molecule drugs that inhibit both transcription factors leads to synergistic decreases in cell proliferation in cell lines and patient-derived organoid models. This study demonstrates that GR and STAT3 cooperate to regulate the basal-like breast cancer gene expression program and provides the basis for improved therapy for basal-like triple negative breast cancer through rational combination of STAT3 and GR inhibitors.

Oncoplastic Surgery in the Large-Breasted Breast Cancer gene Patient: A Staged Step to Enable Nipple Sparing Mastectomy

2021 ◽  
pp. 000313482110234
Author(s):  
Jacob Radparvar ◽  
Charoo Piplani ◽  
Abhishek Chatterjee ◽  
Salvatore M. Nardello
Keyword(s):  
Breast Cancer ◽  
Genetic Testing ◽  
Multidisciplinary Approach ◽  
Triple Negative ◽  
Cancer Gene ◽  
Inclusion Criteria ◽  
Technical Advances ◽  
Nipple Sparing Mastectomy ◽  
Nipple Sparing ◽  
Breast Cancer Gene

Patients with macromastia and/or moderate-severe ptosis who desire mastectomy are typically offered skin sparing mastectomies. Recent technical advances have broadened the inclusion criteria to allow for nipple sparing mastectomy (NSM) in this population; however, they have been limited to patients with unifocal disease. We report on the multidisciplinary approach used to offer a NSM to a patient with multicentric triple-negative breast cancer and symptomatic macromastia with severe ptosis in the setting of positive genetic testing. We discuss the combination of a staged oncoplastic approach with neoadjuvant and adjuvant chemotherapy, as well as the foundations of these approaches. We encourage further research and inclusion of patients such as ours in the criteria for NSM.

Identification of new therapeutic leads for triple negative breast cancer subtypes

Planta Medica ◽  
2015 ◽  
Vol 81 (11) ◽  
Author(s):  
AJ Robles ◽  
L Du ◽  
S Cai ◽  
RH Cichewicz ◽  
SL Mooberry
Keyword(s):  
Breast Cancer ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Breast Cancer Subtypes ◽  
Cancer Subtypes ◽  
Therapeutic Leads

Psychosomatische Aspekte der Beratung bei erblichem Brustund Ovarialkarzinom

2010 ◽  
Vol 01 (01) ◽  
pp. 26-31
Author(s):  
D. Gadzicki ◽  
M. Neises
Keyword(s):  
Breast Cancer ◽  
Psychische Belastungen ◽  
Cancer Gene ◽  
Psychosomatische Aspekte ◽  
Emotionale Belastung ◽  
Breast Cancer Gene

ZusammenfassungDer Nachweis der Gene BRCA (breast cancer gene) 1 und 2 in den Jahren 1994 und 1995 war die Voraussetzung für die Diagnostik genetischer Grundlagen des familiären Mamma- und Ovarialkarzinoms. Eine Mutation in einem dieser Gene ist der wichtigste Risikofaktor für die Entstehung eines solchen Karzinoms. Etwa 5–10 % aller Mamma- und Ovarialkarzinome sind durch genetische Veranlagung bedingt. Die Möglichkeiten der prädiktiven Medizin können sowohl Entlastung, aber auch psychische Belastungen der Ratsuchenden nach sich ziehen. Die Kenntnis der eigenen Prognose oder die anderer innerhalb der Familie kann die Kommunikation und damit die Familienbeziehungen belasten. Die in der Regel noch gesunde Frau wird in der Beratung oft zum ersten Mal damit konfrontiert, dass die Erkrankung potenziell alle in der Familie und auch sie im Laufe ihres Lebens betreffen kann. Diese emotionale Belastung sollte in besonderer Weise berücksichtigt werden. Dabei ist innerhalb der Familie die Autonomie aller mit einem Recht auf Wissen, aber auch Nichtwissen sicherzustellen.

Immediate and long-term results of the first line chemotherapy in patients with metastatic triple negative breast cancer. Final analysis of randomized study

2020 ◽  
pp. 75-80
Author(s):  
S.A. Lyalkin ◽  
◽  
L.A. Syvak ◽  
N.O. Verevkina ◽  
◽  
...  
Keyword(s):  
Breast Cancer ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Randomized Study ◽  
Progression Free Survival ◽  
First Line ◽  
Free Survival ◽  
Group 2 ◽  
Line Chemotherapy ◽  
Group 1

The objective: was to evaluate the efficacy of the first line chemotherapy in patients with metastatic triple negative breast cancer (TNBC). Materials and methods. Open randomized study was performed including 122 patients with metastatic TNBC. The efficacy and safety of the first line chemotherapy of regimens АТ (n=59) – group 1, patients received doxorubicine 60 мг/м2 and paclitaxel 175 мг/м2 and ТР (n=63) – group 2, patients received paclitaxel 175 мг/м2 and carboplatin AUC 5 were evaluated. Results. The median duration of response was 9.5 months (4.5–13.25 months) in patients received AT regimen and 8.5 months (4.7–12.25 months), in TP regimen; no statistically significant differences were observed, р=0.836. The median progression free survival was 7 months (95% CI 5–26 months) in group 1 and 7.5 months (95% CI 6–35 months) in group 2, p=0.85. Both chemotherapy regimens (AT and TP) had mild or moderate toxicity profiles (grade 1 or 2 in most patients). No significant difference in gastrointestinal toxicity was observed. The incidence of grade 3–4 neutropenia was higher in patients of group 2 (TP regimen): 42.8% versus 27% (р<0.05). Conclusions. Both regimens of chemotherapy (AT and TP) are appropriate to use in the first line setting in patients with metastatic TNBC. Key words: metastatic triple negative breast cancer, chemotherapy, progression free survival, chemotherapy toxicity.

Sign in / Sign up

Export Citation Format

Share Document